Recommended

Lilly demonstrates alopecia areata promise in major study
Novartis bets $12bn on potential first-in-class RNA therapeutics
Process analytical tool could aid real-time monitoring in vaccine manufacturing
CPHI Pharma Awards 2025 winners announced
Drug delivery study offers potential “paradigm shift” in restenosis
Lilly AI supercomputer set to advance pharma manufacturing
FDA draft guidance to streamline biosimilar development
Novo Nordisk bids $6.5 billion for Metsera
news

Sandoz breaks ground on new European biosimilar plant

2
SHARES

The new investment will help Sandoz to expand its European biosimilar manufacturing capacity and ensure reliable and sustainable supply in the region.

Sandoz biosimilars Slovenia

Render of the planned biosimilar manufacturing facility in Brnik, Slovenia. Credit: Sandoz

Sandoz has begun construction of a new biosimilars production facility in Brnik, Slovenia.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The $440 million centre will manufacture injectable sterile products, bringing the company’s total planned and ongoing investment in the country to over $1.1 billion before the end of the decade, by 2029.

The new high-tech facility will produce both existing and upcoming biosimilar medicines in Sandoz’s portfolio. The site will have a variety of manufacturing capabilities, including preparation, filling, assembly and packaging, in addition to quality control (QC) laboratories.

“… With a commitment of over $1.1 billion, we are proud to significantly expand our biosimilar manufacturing capacity in Europe as Slovenia’s largest direct foreign investor,” Richard Saynor, Chief Executive Officer of Sandoz commented.

Ensuring a reliable supply of biosimilars in Europe 

“… With a commitment of over $1.1 billion, we are proud to significantly expand our biosimilar manufacturing capacity in Europe as Slovenia’s largest direct foreign investor”

Build of Sandoz’s new biosimilars site in Slovenia aligns with its strategic plan to enhance its ability to provide high-quality, affordable biosimilars to patients across the globe. Moreover, the plant is intended to help Sandoz take advantage of the unique market opportunity, considering value of biosimilar patent expiries are expected to reach $222 billion over the next decade, based on IP databases; internal analysis and Evaluate Pharma, according to Sandoz.

“Our investment in biomanufacturing in the heart of Europe marks another important milestone in building our own independent manufacturing network – one that enhances our control, resilience and agility across the global supply chain,” Glenn Gerecke, Chief Manufacturing and Supply Officer at Sandoz shared.

The new facility in Slovenia aligns with the company’s commitment to in-house manufacturing, supporting its goal of developing an end-to-end leading European biosimilar hub. Sandoz also has ongoing investments in the country—a new biosimilar drug substance production centre in Lendava and a biosimilar development centre in Ljubljana. 

Share via
Share via